Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,209.01
(
1.02%
)
US TECH 100
26,715.60
(
0.96%
)
Dow Jones
49,652.14
(
1.62%
)
Brent Oil
110.84
(
0.44%
)
Bitcoin
77,097.71
(
1.01%
)
News Focus
News Focus
Post# of 257473
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122916
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: bladerunner1717 post# 198785

Monday, 07/25/2016 11:52:18 AM

Monday, July 25, 2016 11:52:18 AM

Post# of 257473
TBRA -58% on phase-2b NASH data from CENTAUR trial:

http://finance.yahoo.com/news/tobira-therapeutics-announces-clinically-statistically-120000416.html

Although the study did not meet its primary endpoint of a two-point reduction in the NAFLD Activity Score, CENTAUR did demonstrate a clinically and statistically significant improvement in fibrosis of at least one stage without worsening of NASH, one of two key secondary endpoints, after only one year of treatment.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today